UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials

Diabetes, obesity & metabolism, 2020-04, Vol.22 (4), p.699-704

2020

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6

Frontiers in endocrinology (Lausanne), 2021-03, Vol.12, p.645566-645566

2021

Link zum Volltext

Verfügbarkeit prüfen

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Diabetes, obesity & metabolism, 2017-02, Vol.19 (2), p.216-227

2017

Link zum Volltext

Verfügbarkeit prüfen

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists

Diabetes, obesity & metabolism, 2020-10, Vol.22 (10), p.1886-1891

2020

Link zum Volltext

Verfügbarkeit prüfen

SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?

Endocrinology (Philadelphia), 2020-08, Vol.161 (8), p.1

2020

Link zum Volltext

Verfügbarkeit prüfen

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

The journal of clinical endocrinology and metabolism, 2022-01, Vol.107 (1), p.1-9

2022

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal changes in fasting and glucose-stimulated GLP-1 and GIP in healthy older subjects

The journal of clinical endocrinology and metabolism, 2019-12, Vol.104 (12), p.6201-6206

2019

Link zum Volltext

Verfügbarkeit prüfen

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

Diabetes, obesity & metabolism, 2017-09, Vol.19 (9), p.1327-1328

2017

Link zum Volltext

Verfügbarkeit prüfen

Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

The journal of clinical endocrinology and metabolism, , Vol.87 (3), p.1239-1246

Link zum Volltext

Verfügbarkeit prüfen

GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?

The lancet. Diabetes & endocrinology, 2016-12, Vol.4 (12), p.963-964

2016

Link zum Volltext

Verfügbarkeit prüfen

Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment

Diabetes, obesity & metabolism, 2016-11, Vol.18 (11), p.1100-1109

2016

Link zum Volltext

Verfügbarkeit prüfen

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2450-2458

2019

Link zum Volltext

Verfügbarkeit prüfen

Liraglutide and Glycaemic Outcomes in the LEADER Trial

Diabetes therapy, 2018-12, Vol.9 (6), p.2383-2392

2018

Link zum Volltext

Verfügbarkeit prüfen

Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?

Nature clinical practice. Endocrinology & metabolism, 2008-11, Vol.4 (11), p.606-607

2008

Link zum Volltext

Verfügbarkeit prüfen

Gastric Inhibitory Polypeptide: the neglected incretin revisited

Regulatory Peptides, 2002-07, Vol.107 (1), p.1-13

2002

Link zum Volltext

Verfügbarkeit prüfen

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

European journal of endocrinology, 2019-12, Vol.181 (6), p.R211

2019

Link zum Volltext

Verfügbarkeit prüfen

Diabetes: Incretin mimetics and insulin - closing the gap to normoglycaemia

Nature reviews. Endocrinology, 2016-12, Vol.12 (12), p.689

2016

Link zum Volltext

Verfügbarkeit prüfen

Therapie des Typ-2-Diabetes

Diabetologie (Online), 2024-03, Vol.20 (2), p.212-260

2024

Link zum Volltext

Verfügbarkeit prüfen

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide

The journal of clinical endocrinology and metabolism, 2000-10, Vol.85 (10), p.3575-3581

2000

Link zum Volltext

Verfügbarkeit prüfen

Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans

American journal of physiology: endocrinology and metabolism, 2007-09, Vol.293 (3), p.E849-E856

2007

Link zum Volltext

Verfügbarkeit prüfen

Veränderungen der Sekretion und biologischen Wirksamkeit von Inkretinhormonen bei Typ-2-Diabetes

Diabetologie (Online), 2024-03, Vol.20 (2), p.201-211

2024

Link zum Volltext

Verfügbarkeit prüfen

Therapie des Typ-2-Diabetes

Diabetologie (Online), 2023-07, Vol.19 (5), p.658-697

2023

Link zum Volltext

Verfügbarkeit prüfen

Therapie des Typ-2-Diabetes

Diabetologie (Online), 2022-07, Vol.18 (5), p.623-656

2022

Link zum Volltext

Verfügbarkeit prüfen

Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

The journal of clinical endocrinology and metabolism, 2002-03, Vol.87 (3), p.1239-1246

2002

Link zum Volltext

Verfügbarkeit prüfen

Therapie des Typ-2-Diabetes

Diabetologe, 2021-06, Vol.17 (4), p.422-447

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 36

Suche als RSS-Feed

Aktive Filter

ThemaEndocrinology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(36)

Sprache

Englisch
(28)
Japanisch
(22)
Deutsch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Endocrinology & Metabolism
(21)
Diabetes
(19)
Endocrinology, Diabetes And Metabolism
(19)
Internal Medicine
(19)
Type 2 Diabetes
(12)
Diabetes Mellitus
(11)
Male
(11)
Biochemistry
(10)
Female
(10)
Medicine
(10)
Medicine & Public Health
(10)
Clinical Biochemistry
(9)
Diabetes Mellitus, Type 2 - Drug Therapy
(9)
Glucagon-Like Peptide 1
(9)
Glucose
(9)
Insulin
(9)

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists

SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

Longitudinal changes in fasting and glucose-stimulated GLP-1 and GIP in healthy older subjects

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?

Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial

Liraglutide and Glycaemic Outcomes in the LEADER Trial

Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?

Gastric Inhibitory Polypeptide: the neglected incretin revisited

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

Diabetes: Incretin mimetics and insulin - closing the gap to normoglycaemia

Therapie des Typ-2-Diabetes

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide

Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans

Veränderungen der Sekretion und biologischen Wirksamkeit von Inkretinhormonen bei Typ-2-Diabetes

Therapie des Typ-2-Diabetes

Therapie des Typ-2-Diabetes

Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

Therapie des Typ-2-Diabetes

Aktive Filter

Suchergebnisse filtern